Please upgrade your browser.
The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions.
The present study aimed to assess the clinicopathological characteristics and the prognosis of renal cell carcinoma (RCC) in children.
A new cutting-edge cancer centre dedicated to robotic surgery, cancer imaging and drug discovery is launched today, putting London at the forefront of cancer research.
TopAbstracts in Renal Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days. Over 2000 peer-reviewed journals are covered by TopAbstracts.
Frequent Dose Interruptions are Required for Patients Receiving Oral Kinase Inhibitor Therapy for Advanced Renal Cell Carcinoma
The experience suggests that the first 4 weeks of treatment is the most likely timeframe within which drug reactions occur. Therefore, careful monitoring and possibly additional clinical visits are warranted during this time period. Although a significant percentage of patients require dose modification, many can be restarted and titrated up to the targeted dose.
Vining says the specialty of radiology needs better practice guidelines on how to handle these. About 10 percent of CT-screened patients will have a significant extracolonic finding, such as lung or kidney cancer. The majority of extracolonic findings, however, are benign entities such as kidney and gall stones or benign tumors.
Histone Methyltransferase Gene SETD2 Is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma
Consistent with this function, the authors observed loss or a decrease of H3K36me3 in 7 out of the 10 cRCC cell lines. Identification of missense mutations in 2 out of 10 primary cRCC tumor samples added support to the involvement of loss of SETD2 function in the development of cRCC tumors.
Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin
Recommended phase II doses of this combination are sorafenib 400 mg twice daily and tanespimycin 400 mg/m2 on days 1, 8 and 15 every 28 days. Clinical and pharmacodynamic activity was observed in kidney cancer and melanoma.
The findings from this consortiumbased study do not support the hypothesis that vitamin D is inversely associated with the risk of kidney cancer overall or with renal cell carcinoma specifically.
Combined Renal Sinus Fat and Perinephric Fat Renal Cell Carcinoma Invasion Has a Worse Prognosis Than Either Alone
Patients with combined renal sinus and perinephric fat invasion had a worse prognosis than those with either alone. Considerations should be made to stage these cases accordingly.
|NeonCRM by Neon One|